EXPRESSION OF PROGRAMMED CELL DEATH RECEPTOR IN ENDOMETRIAL CANCER PATIENTS WITH METABOLIC DISORDERS.

Autor:	Kuzmenko OV; Grigoriev Institute for Medical Radiology and Oncology, NAMS of Ukraine, Kharkiv 61024, Ukraine., Sorochan PP; Grigoriev Institute for Medical Radiology and Oncology, NAMS of Ukraine, Kharkiv 61024, Ukraine., Gromakova IS; Grigoriev Institute for Medical Radiology and Oncology, NAMS of Ukraine, Kharkiv 61024, Ukraine., Shevtsov VG; Grigoriev Institute for Medical Radiology and Oncology, NAMS of Ukraine, Kharkiv 61024, Ukraine., Ivanenko MO; Grigoriev Institute for Medical Radiology and Oncology, NAMS of Ukraine, Kharkiv 61024, Ukraine., Polozova MV; Grigoriev Institute for Medical Radiology and Oncology, NAMS of Ukraine, Kharkiv 61024, Ukraine.
Jazyk:	angličtina
Zdroj:	Experimental oncology [Exp Oncol] 2023 Jun 26; Vol. 45 (1), pp. 44-50. Date of Electronic Publication: 2023 Jun 26.
DOI:	10.15407/exp-oncology.2023.01.044
Abstrakt:	Aim: To study the expression of the programmed cell death receptor (PD-1) and its ligand (PD-L1) by immunocompetent cells in endometrial cancer patients with metabolic disorders. Materials and Methods: Populations and subpopulations of lymphocytes were analyzed by flow cytometry. Antibodies against CD279 were used to detect PD-1 on the CD4+ and CD8+ T cells. Antibodies against CD14 and CD274 were used to detect PD-L1 on monocytes. Results: In patients with severe metabolic disorders, the expression of PD-1 on CD8+ and CD4+ lymphocytes and the expression of the corresponding PD-L1 on CD14+ cells before treatment and after radiation therapy were higher than in the control group. Conclusion: Theincreased expression of PD-1 and PD-L1 receptors by immunocompetent cells can be considered a new prognostic marker in endometrial cancer patients with morbid obesity.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu